- Home
- WNW vs CDT Comparison
WNW vs CDT Comparison
Compare WNW & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- CDT
- Stock Information
- Founded
- WNW 2015
- CDT 2019
- Country
- WNW China
- CDT United States
- Employees
- WNW N/A
- CDT N/A
- Industry
- WNW Catalog/Specialty Distribution
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- WNW Consumer Discretionary
- CDT Health Care
- Exchange
- WNW Nasdaq
- CDT Nasdaq
- Market Cap
- WNW 5.4M
- CDT 4.6M
- IPO Year
- WNW 2020
- CDT N/A
- Fundamental
- Price
- WNW $1.86
- CDT $1.18
- Analyst Decision
- WNW
- CDT
- Analyst Count
- WNW 0
- CDT 0
- Target Price
- WNW N/A
- CDT N/A
- AVG Volume (30 Days)
- WNW 11.9K
- CDT 160.1K
- Earning Date
- WNW 05-14-2025
- CDT 08-14-2025
- Dividend Yield
- WNW N/A
- CDT N/A
- EPS Growth
- WNW N/A
- CDT N/A
- EPS
- WNW 9.06
- CDT N/A
- Revenue
- WNW $158,485.00
- CDT N/A
- Revenue This Year
- WNW N/A
- CDT N/A
- Revenue Next Year
- WNW N/A
- CDT N/A
- P/E Ratio
- WNW $0.21
- CDT N/A
- Revenue Growth
- WNW N/A
- CDT N/A
- 52 Week Low
- WNW $0.95
- CDT $1.16
- 52 Week High
- WNW $70.00
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- WNW 58.73
- CDT 24.09
- Support Level
- WNW $1.67
- CDT $1.47
- Resistance Level
- WNW $1.76
- CDT $1.36
- Average True Range (ATR)
- WNW 0.10
- CDT 0.11
- MACD
- WNW 0.01
- CDT -0.01
- Stochastic Oscillator
- WNW 86.44
- CDT 3.51
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.